Literature DB >> 15450610

MARKing tau for tangles and toxicity.

Gerard Drewes1.   

Abstract

In healthy neurons, tau proteins regulate microtubule function in the axon. In the brains of individuals with Alzheimer's disease, tau is hyperphosphorylated and aggregated into intraneuronal deposits called neurofibrillary tangles (NFTs). Hyperphosporylation dislodges tau from the microtubule surface, potentially resulting in compromised axonal integrity and the accumulation of toxic tau peptides. Recent biochemical and animal model studies have re-evaluated tau phosphorylation and other aspects of neurofibrillar pathology. The results indicate that phosphorylation of tau's microtubule-binding domain by the protein kinase MARK primes tau for hyperphosphorylation by the kinases GSK-3 and Cdk5, which in turn triggers the aggregation of tau into filaments and tangles. Toxic consequences for the neuron might be exacerbated by tangle formation but are already evident during the early steps of the process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450610     DOI: 10.1016/j.tibs.2004.08.001

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  33 in total

1.  Solution structure of the kinase-associated domain 1 of mouse microtubule-associated protein/microtubule affinity-regulating kinase 3.

Authors:  Naoya Tochio; Seizo Koshiba; Naohiro Kobayashi; Makoto Inoue; Takashi Yabuki; Masaaki Aoki; Eiko Seki; Takayoshi Matsuda; Yasuko Tomo; Yoko Motoda; Atsuo Kobayashi; Akiko Tanaka; Yoshihide Hayashizaki; Takaho Terada; Mikako Shirouzu; Takanori Kigawa; Shigeyuki Yokoyama
Journal:  Protein Sci       Date:  2006-11       Impact factor: 6.725

2.  PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction.

Authors:  Yali Zhang; Huifu Guo; Helen Kwan; Ji-Wu Wang; Jon Kosek; Bingwei Lu
Journal:  Neuron       Date:  2007-01-18       Impact factor: 17.173

Review 3.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 4.  Innate immune activation in Alzheimer's disease.

Authors:  Ming-Ming Wang; Dan Miao; Xi-Peng Cao; Lin Tan; Lan Tan
Journal:  Ann Transl Med       Date:  2018-05

Review 5.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

6.  Combinatorial Tau pseudophosphorylation: markedly different regulatory effects on microtubule assembly and dynamic instability than the sum of the individual parts.

Authors:  Erkan Kiris; Donovan Ventimiglia; Mehmet E Sargin; Michelle R Gaylord; Alphan Altinok; Kenneth Rose; B S Manjunath; Mary Ann Jordan; Leslie Wilson; Stuart C Feinstein
Journal:  J Biol Chem       Date:  2011-02-02       Impact factor: 5.157

7.  Progress in the development of new drugs in Alzheimer's disease.

Authors:  Antoine Piau; F Nourhashémi; C Hein; C Caillaud; B Vellas
Journal:  J Nutr Health Aging       Date:  2011-01       Impact factor: 4.075

8.  Abnormal phosphorylation of tau protein and neuroinflammation induced by laparotomy in an animal model of postoperative delirium.

Authors:  Le Yu; Guanghua Wen; Shoufeng Zhu; Xianwen Hu; Chunxia Huang; Yan Yang
Journal:  Exp Brain Res       Date:  2021-01-07       Impact factor: 1.972

9.  Special Issue on "Cdk5 and Brain Disorders": Prologue.

Authors:  Jyotshnabala Kanungo
Journal:  Brain Disord Ther       Date:  2012-05-31

Review 10.  MAP/microtubule affinity-regulating kinases, microtubule dynamics, and spermatogenesis.

Authors:  Elizabeth I Tang; Dolores D Mruk; C Yan Cheng
Journal:  J Endocrinol       Date:  2013-04-15       Impact factor: 4.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.